In a 72-year-old man with six months of epigastric pain and a sensation of gastric fullness, normal upper gastrointestinal endoscopy, negative Helicobacter pylori testing, and no weight loss or iron‑deficiency anemia, which of the following is NOT appropriate: A) Empiric proton‑pump inhibitor therapy, B) Treatment with tricyclic antidepressants or metoclopramide‑type prokinetics, C) Empiric Helicobacter pylori eradication therapy, D) Empiric therapy with non‑absorbable antibiotics such as rifaximin, E) Avoidance of alcohol, caffeine, and smoking?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

The Incorrect Option is C: Empiric Helicobacter pylori Eradication Therapy

In this 72-year-old man with functional dyspepsia and documented negative H. pylori testing, empiric H. pylori eradication therapy is NOT appropriate and represents the incorrect answer. Treating for an infection that has already been ruled out contradicts evidence-based guidelines and exposes the patient to unnecessary antibiotics without potential benefit.

Why Option C is Incorrect

The 2022 British Society of Gastroenterology guidelines explicitly state that eradication therapy is only efficacious for H. pylori-positive patients with functional dyspepsia 1. The patient has already undergone H. pylori testing with negative results, making empiric eradication therapy both illogical and potentially harmful through unnecessary antibiotic exposure.

The guidelines emphasize that all patients with functional dyspepsia should be offered testing for H. pylori, but eradication is reserved for those who test positive 1. There is no role for empiric treatment when testing has already been performed and returned negative.

Why the Other Options ARE Appropriate

Option A: Empiric PPI Therapy - CORRECT

The BSG guidelines provide a strong recommendation (high-quality evidence) that patients without H. pylori infection should be offered empirical acid suppression therapy 1. PPIs are first-line treatment for functional dyspepsia in H. pylori-negative patients, with proven efficacy and good tolerability. The lowest effective dose should be used 1.

Option B: TCAs or Prokinetics - CORRECT

  • Tricyclic antidepressants are strongly recommended as second-line treatment (moderate-quality evidence) when first-line therapies fail 1. They should be started at low doses (e.g., 10 mg amitriptyline) and titrated to 30-50 mg daily.
  • Prokinetics like metoclopramide may be efficacious (weak recommendation, low-quality evidence for most agents) 1. While metoclopramide carries risks of tardive dyskinesia with prolonged use 2, it remains an appropriate option for short-term symptom management in functional dyspepsia.

Option D: Rifaximin - CORRECT (with caveats)

While rifaximin is not prominently featured in the BSG guidelines for functional dyspepsia, it has been studied for H. pylori eradication 3, 4 and has a role in other gastrointestinal conditions. The FDA label confirms its use in various GI disorders 5. Though not first-line, empiric rifaximin therapy could be considered in refractory cases, particularly given its excellent safety profile and minimal systemic absorption.

Option E: Lifestyle Modifications - CORRECT

The BSG guidelines strongly recommend that all patients with functional dyspepsia are advised to take regular aerobic exercise 1. Lifestyle changes including avoidance of symptom triggers (alcohol, caffeine) and smoking cessation are appropriate conservative measures, though dietary evidence is limited 1.

Clinical Algorithm for This Patient

  1. Confirm diagnosis: Normal endoscopy + negative H. pylori = functional dyspepsia ✓
  2. First-line: Empiric PPI therapy (strong recommendation)
  3. If PPI fails: Trial of prokinetic therapy
  4. Second-line: Tricyclic antidepressants (strong recommendation)
  5. Throughout: Lifestyle modifications including exercise, avoiding triggers, smoking cessation
  6. NOT indicated: H. pylori eradication when testing is negative

Key Pitfall to Avoid

Do not treat empirically for H. pylori when testing has already been performed and is negative. This represents inappropriate antibiotic use, contributes to antimicrobial resistance, exposes patients to unnecessary side effects, and provides no therapeutic benefit. The 2024 ACG guidelines on H. pylori treatment emphasize that eradication therapy should only be given to confirmed positive cases 6.

References

3
Research

Rifaximin and Helicobacter pylori eradication.

European review for medical and pharmacological sciences, 1997

6
Research

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

The American journal of gastroenterology, 2024

Related Questions

What is the recommended management for dyspepsia in an adult patient without alarm features, including lifestyle modifications, Helicobacter pylori testing and eradication, and appropriate pharmacologic therapy?
How do I differentiate functional dyspepsia from Helicobacter pylori infection in a patient with dyspeptic symptoms?
What is the next step in investigating postprandial abdominal pain in a patient with negative Helicobacter pylori and celiac disease testing who cannot tolerate GERD medication?
Is a negative Helicobacter pylori IgG antibody test reliable in a patient taking famotidine 20 mg twice daily and sucralfate 1 g four times daily, and what is the appropriate next step if dyspeptic symptoms persist?
Can undiagnosed Helicobacter pylori infection cause refractory upper gastrointestinal symptoms even when spending time outdoors (e.g., under trees)?
What is the recommended management for cutaneous lupus erythematosus, including photoprotection and pharmacologic therapy?
Should the dose of the combined oral contraceptive Amena (ethinyl estradiol + norethisterone) be reduced in a woman with rising alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels?
Is systemic lupus erythematosus (SLE) deadly?
What is the preferred initial treatment for recurrent seminoma in a patient who has not previously received chemotherapy?
Can a diabetic male with androgenic alopecia be treated with finasteride, and what dose and monitoring are recommended?
Does resistance training to increase muscle mass increase resting energy expenditure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.